Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1293-1300

  Czabanka, Marcus ^a   Vinci, Mara ^b   Heppner, Frank ^a   Ullrich, Axel ^c   Vajkoczy, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Antiangiogenic treatment; Chemotherapy; Sunitinib; Tumor microhemodynamics; Tumor vessel normalization

Indexed keywords

ANGIOGENESIS INHIBITOR; DOXORUBICIN; SUNITINIB; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; DESMIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOFLUORESCENCE; BLOOD FLOW VELOCITY; BLOOD VESSEL DIAMETER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DENSITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MICROCIRCULATION; MICROSCOPY; MICROVASCULATURE; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR ESCAPE; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; CELL DIVISION; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DESMIN; DOXORUBICIN; GLIOBLASTOMA; HEMODYNAMICS; INDOLES; MICE; MICE, NUDE; MICROCIRCULATION; PYRROLES;

EID: 60549117718     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24019     Document Type: Article

References (25)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004:350:2335-42.
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
4. Kernel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312:1171-5.
5. Roskoski R, Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Comraun 2007;356:323-8.
6. Demetri GD, van Oosterom AT, Garrett CR, Blaekstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan J A, Desai J, Fletcher CD, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imati-nib: a randomised controlled trial. Lancet 2006;368:1329-38.
7. Motzer RJ, Hutson TE, Tomezak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engi J Med 2007; 356:115-24.
8. Teicher BA, A systems approach to cancer therapy, (Antioncogenics + standard cytotoxics →mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-72.
9. Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD, Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab 1998;18:510-20.
10. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TA, Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1:31-41.
11. Baker M, Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 1974;7:131-43.
12. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes LIP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
14. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU 11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004:7:225-33.
15. Jain RK, di Toraaso E, Duda DG, Loeffler JS, Sorensen AG, Batche-ior TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
16. Seandel M, Shia J, Linkov I, Maki RG, Antonescu CR, Dupont J. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects, Clin Cancer Res 2006; 12: 6203-4.
17. Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM. Improving deliverv of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005:103:1561-70.
18. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin- 1, and matrix metailoproteinases. Cancer Cell 2004;6:553-63.
19. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008;14:1540-9.
20. Weis SM. Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol 2008;15:243-9.
21. Vajkoczy P, Menger MD, Vascular microenvironment in gliomas. Cancer Treat Res 2004;! 17:249-62.
22. Biansfield JA, Caragacianu D, Alexander HR, III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008:14:270-80,
23. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994;54:4564-8.
24. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW, Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc Res 1993;46:231-53.
25. Willett CG, Boucher Y, di Tomaso E, Duda DG. Munn LL. Tong RT. Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med 200440:145-7.